Research Analysts Set Expectations for PBYI FY2025 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a note issued to investors on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.26 per share for the year, up from their prior forecast of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2026 earnings at $0.29 EPS and FY2026 earnings at $0.77 EPS.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter last year, the business posted $0.12 earnings per share.

A number of other brokerages also recently commented on PBYI. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd.

Puma Biotechnology Stock Performance

Shares of Puma Biotechnology stock opened at $3.08 on Friday. Puma Biotechnology has a 12 month low of $2.22 and a 12 month high of $7.73. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a market cap of $151.19 million, a PE ratio of 6.42 and a beta of 1.08. The business has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $2.99.

Institutional Trading of Puma Biotechnology

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Puma Biotechnology during the 3rd quarter valued at $34,000. Franklin Resources Inc. acquired a new position in shares of Puma Biotechnology in the third quarter valued at approximately $41,000. Victory Capital Management Inc. acquired a new stake in Puma Biotechnology during the 2nd quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Puma Biotechnology in the 3rd quarter worth approximately $44,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at $58,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.